| Name | Title | Contact Details |
|---|
First Primary Care is a direct primary care practice that provides personalized, accessible, cost-effective, modern care to each member of your family. They offer unrestricted, no-wait access to primary care physicians through in-person visits, text, o...
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Accel Clinical Research is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Tegria, we believe that the right technology and tools can help make care more effective for more people. Launched in 2020 with support from Providence, one of the country`s largest health systems, Tegria combines innovative technologies and services to create powerful solutions that simplify healthcare for everyone involved. We built Tegria to make a difference, not only for our customers, but for our communities. We deliver complete solutions to streamline the process of receiving and delivering care, from first visit to follow-up and beyond.
Apervita is the trusted healthcare collaboration platform for quality measurement, clinical intelligence, value optimization and interoperability. We empower payers and providers and other stakeholders to more efficiently and effectively measure clinical and financial performance, improve clinical quality and administer and run analytics on value-based contracts. By providing an independent, secure, trusted platform to perform shared analyses, Apervita uniquely allows stakeholders to gain mutual, continuous clinical and financial insights and integrate those insights in various systems and workflows simultaneously and at scale. Serving more than one in three hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 10 billion value-based computations and insights for our clients every year. Serving more than one in five hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 1 billion value-based computations and insights for our clients every year. Founded in 2012, the company maintains office locations in Chicago and Boston.